Table 3 Active clinical trials combining radiation with TGF-β blockade or GM-CSF
From: Current clinical trials testing the combination of immunotherapy with radiotherapy
NCT Number | Phases | Title | Condition | Intervention | RT Details | Enrollment | Sponsor/Collaborators |
|---|---|---|---|---|---|---|---|
Anti-TGF- β | |||||||
NCT02538471 | Phase 2 | LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer | Metastatic Breast Cancer | LY2157299 | RT, 7.5 Gy × 3 fx | 28 | Weill Medical College of Cornell University|University of California, Los Angeles |
NCT02581787 | Phase 1|Phase 2 | SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer | Stage IA-B NSCLC | Fresolimumab | SBRT, 4 fx | 60 | Maximilian Diehn|National Cancer Institute (NCI)|Stanford University |
GM-CSF | |||||||
NCT02623595 | Phase 2 | A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy | Non-small cell lung cancer | GM-CSF | SBRT, 10 Gy × 5 fx | 60 | Wuhan University|Tongji Hospital|Hubei Cancer Hospital |
NCT02663440 | Phase 2 | Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme | Glioblastoma | GM-CSF, Temozolomide | Hypofx IMRT | 41 | Zhejiang Cancer Hospital |
NCT02677155 | Phase 2 | Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma | Follicular Lymphoma | GM-CSF, Pembrolizumab, Rituximab, autologous dendritic cells | 8 Gy × 1 | 20 | Oslo University Hospital|Norwegian Cancer Society|Merck Sharp & Dohme Corp. |
NCT02648282 | Phase 2 | Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer | Pancreatic Cancer | GVAX, Cyclophosphamide, Pembrolizumab | SBRT, 6.6 Gy × 5 fx | 54 | Sidney Kimmel Comprehensive Cancer Center|Merck Sharp & Dohme Corp. |